Screener
Dianthus Therapeutics DNTH License — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Revenues: | ||
| License revenue | $463 | $1,163 |
| Operating expenses: | ||
| Research and development | 34,528 | 27,003 |
| General and administrative | 12,468 | 7,337 |
| Total operating expenses | 46,996 | 34,340 |
| Loss from operations | (46,533) | (33,177) |
| Other income/(expense): |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's license — revenue?
- Dianthus Therapeutics (DNTH) reported license — revenue of $463K in Q1 2026.
- How has Dianthus Therapeutics's license — revenue changed year-over-year?
- Dianthus Therapeutics's license — revenue decreased by 60.2% year-over-year, from $1.16M to $463K.
- What does license — revenue mean?
- This metric represents the total gross revenue recognized from licensing agreements or intellectual property arrangements within a specific business segment, excluding any pass-through taxes. It reflects the company's ability to monetize its proprietary technology or research assets through partnerships or commercial collaborations. Growth in this figure indicates successful commercialization of the company's pipeline and the strength of its intellectual property portfolio.
Ask your AI about Dianthus Therapeutics's license — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude